Tolerogenic Vehicles of Antigens in the Antigen-Specific Immunotherapy for Autoimmunity
Nasrin Aktar,Tingting Chen,Ahmed Moudud,Suowen Xu,Xiaohui Zhou
DOI: https://doi.org/10.1016/j.jddst.2021.102772
IF: 5
2021-01-01
Journal of Drug Delivery Science and Technology
Abstract:Autoimmunity consequences from the imbalance between immune response, tolerance, and the production of a considerable amount of antibodies or autoreactive T cells is attributed to reduced tolerance of the immune system to autoantigens. In comparison, antigen-specific immunotherapy for autoimmunity provides more effects, such as a reduced side impact and clinical effect than nonspecific immunosuppressant's. While several clinical trials for autoimmunity have emerged on soluble antigens, peptide-MHC complexes, and altered peptide ligands therapies have become frustrating, with few exceptions. Inadequate antigen delivery is considered to be one of the most influential factors for the failure of antigen-specific immunotherapy, hence more attention is needed to optimizing antigen distribution. Here, we reviewed tolerogenic vehicles (dendritic cells, apoptotic cells, red blood cells, nanoparticles, microparticles, and transgenic plants) capable to load autoantigens or peptides in the antigen-specific immunotherapy for autoimmunity, targeting B cells, T cells, and antigen-presenting cells.